The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia.
There is strong evidence that intravenous administration of ketamine following a standardized protocol could be used as a diagnostic test for a central sensitization in the central nervous system in patients with FM. The combination of a weak opioid and an NMDA-receptor antagonist with few side effects is presently a promise for treatment of pain in a subgroup of patients with FM. The response to intravenously administered ketamine may help select patients for this treatment modality.
Henriksson
Karl G
KG
Department of Rehabilitation Medicine, Faculty of Health Sciences, Linköping University, Pain Clinic, University Hospital, Linköping S-581 85, Sweden. karl-g@telia.com
Sörensen
Jan
J
D003915:Dextromethorphan / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005356:Fibromyalgia / Q000188:drug therapy*; D006801:Humans; D007649:Ketamine / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine; D003915:Dextromethorphan